A Cannabis-Oil Epilepsy Study Defined Tolerance by Dose or Seizure Changes

A study's definition of tolerance determines which patients are counted. In a prospective epilepsy cohort receiving CBD-enriched cannabis oil, tolerance meant a specified increase in dose or seizure frequency under defined treatment conditions. It was not a direct measurement of receptor adaptation.

The formulation contained both CBD and THC

Ninety-two patients with treatment-resistant epilepsy received a cannabis extract described as having a 20:1 CBD-to-THC ratio. Ages ranged from childhood to adulthood. Seizure frequency was reported by patients or parents at clinic visits.

Several denominators described different outcomes

The abstract reports that eighty-four patients entered the tolerance analysis and twenty-one met its definition. Other reported denominators concerned treatment discontinuation and adverse reactions. These populations should not be interchanged when calculating or describing a rate.

The definition combined two pathways

Tolerance could be recorded following a substantial dose increase prompted by declining efficacy, or a substantial increase in seizure frequency after sufficient treatment duration without changes in other antiseizure medications. Such criteria describe a clinically important pattern but do not independently isolate its biological cause.

The cohort was not a blinded randomized comparison of purified CBD against placebo. Disease fluctuation, treatment decisions and the mixed formulation complicate attribution. The study therefore raises a question about declining effectiveness during continued treatment rather than proving that CBD alone produced pharmacological tolerance in every counted patient. It also does not justify changing an individual's antiseizure medication without clinical management.

Related: interpreting cannabis tolerance claims.

Research cited

Uliel-Sibony S; Hausman-Kedem M; Fattal-Valevski A; Kramer U. Cannabidiol-enriched oil in children and adults with treatment-resistant epilepsy-does tolerance exist? Brain & development (2021). doi:10.1016/j.braindev.2020.06.018. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us